
Upgrades
Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71, compared to year-ago quarter EPS of $0.52. The stock has a 52-week-high of $50.88 and a 52-week-low of $18.07. At the end of the last trading period, Revolution Medicines closed at $18.92.